Key terms
About FATE
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest FATE news
Today
4:46am ET
Hold Rating on Fate Therapeutics Amid Pending Clinical Data and Strategic Pipeline Focus
Today
4:39am ET
Fate Therapeutics: A Promising Contender in Autoimmune Disease Cell Therapy with Innovative FT819 and FT522 Trials
Yesterday
6:20am ET
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Fate Therapeutics (FATE) and Instil Bio (TIL)
May 11
2:00am ET
Fate Therapeutics’ Reporting Strategy: A Double-Edged Sword for Investor Confidence and Share Stability
May 10
10:05am ET
Fate Therapeutics price target lowered to $4 from $7 at Piper Sandler
May 10
8:50am ET
Fate Therapeutics price target lowered to $5 from $7 at Wedbush
May 10
8:47am ET
Wedbush Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
May 10
8:30am ET
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
May 10
8:02am ET
Fate Therapeutics (FATE) Receives a Hold from Piper Sandler
May 10
7:28am ET
Fate Therapeutics price target lowered to $9 from $11 at Canaccord
May 10
6:29am ET
Fate Therapeutics: Strategic Shifts Prompt Hold Rating Amidst Awaited Clinical Results
May 10
5:46am ET
Barclays Sticks to Their Buy Rating for Fate Therapeutics (FATE)
May 09
4:17pm ET
Fate Therapeutics reports Q1 EPS (47c), consensus (49c)
May 09
9:12am ET
Fate Therapeutics Advances in Autoimmune and Cancer Therapies
May 09
8:41am ET
Fate Therapeutics announces first lupus patient treated in Phase 1 FT819 trial
May 06
7:55am ET
Fate Therapeutics (FATE) Gets a Hold from Wedbush
Apr 24
4:50am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)
Apr 18
4:03pm ET
Fate Therapeutics files to sell 3.64M shares of common stock for holders
Mar 28
7:42am ET
Fate Therapeutics price target raised to $6 from $2 at BofA
Mar 28
4:58am ET
Cautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation Concerns
Mar 25
9:10pm ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)
Mar 19
8:46am ET
Fate Therapeutics prices 14.5M shares at $5.50 in underwritten offering
Mar 19
6:28am ET
Fate Therapeutics: A Hold Rating Amidst Financial Uncertainty and Clinical Milestones
Mar 01
1:09am ET
Fate Therapeutics: Buy Rating Affirmed Amid Promising Pipeline and Upcoming Oncology Catalysts
Feb 27
11:57pm ET
Fate Therapeutics: Hold Rating Maintained Amid Anticipation of Pivotal Clinical Data
Feb 27
8:26am ET
Fate Therapeutics price target lowered to $11 from $13 at Canaccord
Feb 27
8:15am ET
Fate Therapeutics price target raised to $7 from $3 at Wedbush
Feb 27
7:49am ET
Oppenheimer Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
Feb 27
7:26am ET
Market Perform: A Cautious Outlook on Fate Therapeutics’ Clinical Progress and Immunology Prospects
Feb 27
6:30am ET
Fate Therapeutics: A Cautious Hold Amidst Upcoming Clinical Milestones and Improved Financial Health
Feb 27
5:50am ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), BioCryst (BCRX) and Veeva Systems (VEEV)
FATE Financials
Key terms
Ad Feedback
FATE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FATE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
